89Zr-Girentuximab
ZiPUP
Phase 1 small_molecule completed
Quick answer
89Zr-Girentuximab for Urothelial Carcinoma is a Phase 1 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Urothelial Carcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed